Results 51 to 60 of about 46,038 (143)

Prediction of deep remission through serum TNF-α level at 1 year of treatment in pediatric Crohn’s disease

Scientific Reports
A pilot study investigated the cytokine profile (IL-6, TNF-α, IL-17 A, and IL-10) at diagnosis, affecting infliximab (IFX) trough levels (TLs) in pediatric patients with Crohn’s disease (CD).
Seon Young Kim, Yiyoung Kwon, Eun Sil Kim, Yoon Zi Kim, Hansol Kim, Yon Ho Choe, Mi Jin Kim   +6 more
doaj   +1 more source

Detection of Anti-Infliximab and Anti-Adalimumab Antibodies Below Manufacture's Threshold in a TDM Cohort Using Signal-to-Noise Ratio. [PDF]

Basic Clin Pharmacol Toxicol
Pedersen L.
europepmc   +1 more source

Safety evaluation of subcutaneous and intravenous administration of infliximab: a real-world study based on the FAERS database. [PDF]

Front Med (Lausanne)
Zheng X, Xie M, Luo H, Cai J, Xu R, Ling T.   +5 more
europepmc   +1 more source

Infliximab-Responsive Severe Ulcerative Colitis With Pyoderma Gangrenosum After IL-6 and IGF-1 Blockade. [PDF]

ACG Case Rep J
Onishi S, Otagiri S, Shinkai A, Watanabe M, Tanaka S, Fujihata K, Aoyama K, Inoue A, Katsurada T, Sakamoto N.   +9 more
europepmc   +1 more source

Severe cerebellitis as a manifestation of infliximab-associated overlap of neurosarcoidosis and myelin oligodendrocyte glycoprotein antibody-associated disease - case report. [PDF]

Front Immunol
Hütter G, Winkelhausen M, Tönges L, Gold R, Faissner S.   +4 more
europepmc   +1 more source

GENERATIVE AI TOWARDS A COMPARATIVE ANALYSIS OF HOSPITALIZATION RATES AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH INFLIXIMAB, VEDOLIZUMAB, AND TOFACITINIB IN THE PUBLIC HEALTHCARE SYSTEM IN BRAZIL: A NATIONWIDE STUDY. [PDF]

Arq Gastroenterol
Valverde DA, Quaresma AB, Villamil MPG, Moraes TP, Kotze PG.   +4 more
europepmc   +1 more source

Distinguishing Detectable From Clinically Relevant Immunogenicity With Subcutaneous Infliximab. [PDF]

United European Gastroenterol J
Lu MY, Shu YP, Shi R.
europepmc   +1 more source

Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation <i>in vivo</i>. [PDF]

Front Immunol
Yu Y, Zhan L, Tang Z.
europepmc   +1 more source

Early infliximab rescue therapy is associated with reduced length of stay in patients with acute severe ulcerative colitis. [PDF]

BMC Gastroenterol
Mohamedrashed M, Yogakanthi S, Bartlett R, Chew M, Nedumannil L, Xu ZC, Chauhan A, Lucas S, Lewis D, Little RD, Kashkooli S, Garg M.   +11 more
europepmc   +1 more source

Rare Complications in Crohn's Disease: Diagnostic and Therapeutic Challenge of Dermal Abscesses Caused by Nontuberculous Mycobacteria Following Infliximab Therapy, and Fluoroquinolone-Related Achilles Tendon Rupture. [PDF]

Am J Case Rep
Gupta N, Yadav K, Carter A, Karimian B, Almonte C, Sampath R.   +5 more
europepmc   +1 more source